Compare Marriott International Inc (MAR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs BIO-TECHNE Corp — how do they compare? Marriott International Inc trades at $368.16 (market cap $96.76B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Marriott International Inc is far larger — about 8.7× BIO-TECHNE Corp's market cap, and Marriott International Inc pays the higher dividend (0.8%). Which is the better fit depends on your goals.
| MAR | TECH | |
|---|---|---|
Market Cap | $96.76B | $11.16B |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $72.12 |
52-Week Low | $255.35 | $43.31 |
Enterprise Value | $113.71B | $11.24B |
Dividend Yield | 0.8% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $366.83, up 0.16% on the day, with technical indicators showing a bearish trend near key support at $364. The company reported Q1 2026 EPS of $2.72, beating expectations, and maintains a net income margin of 9.72% amid steady revenue growth. Recent developments include a strategic partnership with Coca-Cola and the launch of an AI-powered travel search tool, Ask Bonvoy, enhancing its digital offerings.
The outlook is mixed: analyst consensus targets $387.92 with 44% buy ratings, but rising debt-to-asset ratios and hotel owner disputes over the Bonvoy program pose risks. Earnings on August 3, 2026, will be critical for confirming growth trajectory amid competitive travel sector pressures.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
